Efficacy and Safety of SBRT in Oligo-metastatic/Persistent/Recurrent Ovarian Cancer

NACompletedINTERVENTIONAL
Enrollment

376

Participants

Timeline

Start Date

March 1, 2021

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions
Ovarian NeoplasmsRecurrent Ovarian CarcinomaOligometastatic Disease
Interventions
RADIATION

Stereotactic body radiotherapy

All patients accrued will be treated with SBRT to all sites of active metastatic disease as per CT scan or PET/CT and/or MRI. A range of schedules and doses are provided, it is advised that the maximum dose that can be achieved whilst meeting the organs at risk planning constraints is prescribed.

Trial Locations (14)

73100

Ospedale Vito Fazzi, Lecce

86100

Responsible Research Hospital, Campobasso

Unknown

S.C. di Radioterapia Oncologica-Azienda Sanitaria locale, Biella

"Azienda Ospedaliera Cannizzaro", Catania

Azienda sanitaria locale Lanciano Vasto Chieti, Chieti

Department of Radiation Oncology, IRCCS San Raffaele Scientific Institute, Milan

Humanitas Clinical and Research Center-IRCCS, Milan

Azienda USL - IRCCS di Reggio Emilia, Reggio Emilia

Fatebenefratelli Isola Tiberina-Gemelli Isola,, Roma

S Maria Hospital, Terni

Azienda Sanitaria Universitaria Friuli Centrale (ASU FC) - SOC Radioterapia, Udine

00100

Campus Biomedico, Roma

Policlinico A. Gemelli, IRCCS, Roma

Università La Sapienza, Roma

All Listed Sponsors
collaborator

Fondazione Policlinico Universitario A. Gemelli, IRCCS

UNKNOWN

lead

Gemelli Molise Hospital

OTHER

NCT04593381 - Efficacy and Safety of SBRT in Oligo-metastatic/Persistent/Recurrent Ovarian Cancer | Biotech Hunter | Biotech Hunter